MedCity News

Happy Health’s Cuffless BP Device Wins FDA Clearance

Roche Puts Up $100M to Pursue Promising But Competitive New Target in Obesity

Roche gains global rights to a Rona Therapeutics RNA interference drug designed to target ALK7, a genetically validated target for obesity and other metabolic indications. The growing field of companies pursuing ALK7 includes GSK and Arrowhead Pharmaceuticals.

By Frank Vinluan

Opinion

Medicare Policy Shouldn’t Be Made in the Shadows

Medicare policy should be transparent and include appropriate notice and stakeholder input. And when a contractor gets it wrong, there should be a clear and rapid way to stop the harm to patients, their relationship with their doctor and the doctor’s practice.

By Dr. Chris Phillips

MedCity Influencers

What Corporate Venture Funds Get Wrong about Strategic Value

Corporate venture funds often chase financial returns while ignoring strategic value. Here’s what it takes to turn healthcare portfolio investments into lasting business impact.

By David M. Rubin

Latest Video

Latest News

BioPharma, Pharma

Asahi Kasei Acquisition Pays Off With FDA Approval for Novel Herpes Drug

Asahi Kasei’s Hovilpri is now approved for treating lesions caused by herpes simplex virus infection. This daily pill came from the $919 million acquisition of AiCuris Anti-Infective Cures.

By Frank Vinluan

Health Tech

Outro Raises $7M To Support Safe Deprescribing

Outro’s funding included participation from Listen Ventures, Cake Ventures, Jason Calicanis’s LAUNCH, Actions Capital, Hannah Grey Ventures, SemperVirens, Brock Recovery Group and Pave Health Ventures.

By Marissa Plescia

MedCity Influencers

Why Pharma Companies Should Look To Social Media For Better Patient Insight

Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.

By Rohit Marwah

MedCity Influencers

Pediatric Innovation Isn’t a Small-Market Problem, It’s an Incentive Problem

Investing in pediatric care is not simply a moral imperative. It is one of the most practical long-term investments the healthcare system can make.

By Scott Xiao

MedCity Influencers

Loneliness And Diabetes: Harnessing an Opportunity for Better Outcomes

Asking the right questions about community support, caregiving responsibilities, emotional well-being, and the availability of trusted social networks can establish important context for a person’s outcomes — and spark conversations about social needs that might never otherwise take place.

By Coni Dennis

Events, Consumer / Employer

Join Us at INVEST Digital Health for a Conversation on Consumer-Centered Care across the Healthcare Ecosystem

Register for INVEST Digital Health, scheduled for October 29 in Dallas, for an engaging discussion on the impact of consumer-centered care from diagnostics to employer benefits and more.

By Stephanie Baum

Devices & Diagnostics

Are Hospital Operating Rooms Ready For FDA’s Expectations for Surgical Robots?

The FDA recently published draft guidance on pre-market testing for robotically-assisted surgical devices, raising timely discussion around whether hospital infrastructures are capable of supporting increasingly complex systems.

By Jenna Congdon

BioPharma, Pharma

TRrexBio’s IPO Bags $116M to Bring the Immune System Back Into Balance

Eli Lilly-partnered TRexBio will apply the IPO proceeds toward clinical development of molecules designed to activate regulatory T cells to mediate immune responses and inflammation. Meanwhile, Retension Pharmaceuticals will use its IPO cash for mid-stage testing of a next-generation hypertension drug.

By Frank Vinluan

MedCity Influencers

What Life Sciences Commercial Teams Can Learn from Digital Health

The pace of change in digital innovation has exposed the ever-widening gap between digital health and Pharma commercial teams. As a result, Pharma is missing out on its ability to significantly improve its commercial model, by focusing on efficiencies vs. truly reinventing.

By Suzy Jackson

BioPharma, Startups, Devices & Diagnostics

Startup Arboretum Sprouts, Bringing a Precision Medicine Approach to Common Diseases

Diagnostics and drug development startup Arboretum LifeSciences launched with $30 million in financing. Its executives say analyses of data from its genetic tests both form the basis of partnerships with big pharma and lead to the formation of new biotech companies — all focused on common diseases.

By Frank Vinluan

Health Tech

Vitalize Secures $31M To Help Hospitals Manage Labor, Capacity

The Series A round was led by Oak HC/FT, with participation from Norwest, .406 Ventures, Constellation Ventures, Y Combinator, Rock Health Capital and MemorialCare Innovation Fund.

By Marissa Plescia

MedCity Influencers

alzheimer's, memory loss and senile dementure

AI Can Flag Cognitive Decline Earlier — Health Systems Still Own What Happens Next

Earlier detection is valuable, but it creates a duty that does not end when an alert appears in the electronic health record. Health systems need to decide, in advance, how a risk signal becomes a clinically accountable pathway.

By Nargiz Noimann

Payers, Providers

Trilliant Health: Misaligned Incentives Are Undermining US Healthcare

Trilliant Health’s report identifies six trends highlighting how misaligned incentives are contributing to rising costs, poor health outcomes, workforce shortages and other systemic problems in U.S. healthcare.

By Marissa Plescia

Health Tech, Artificial Intelligence

Teladoc Health Adds Contactless Vitals and Ambient AI Scribe to Virtual Visit Platform

Teladoc Health announced Wednesday that it is launching two new AI-powered capabilities built into its Solo smart care platform for hospitals and health systems to be used during virtual visits.

By Jenna Congdon

BioPharma, Pharma

Caribou Bio’s Journey With Off-the-Shelf Cell Therapy Reaches the End of the Road

Caribou Biosciences is stopping work on its two remaining cancer cell therapies and exploring strategic alternatives for the business. The move follows the CRISPR biotech company’s failure to secure financing for its clinical trial plans.

By Frank Vinluan